Get the Stockscreener App
42.60
1.31%
0.55
After Hours:
42.60
Vera Therapeutics Inc stock is traded at $42.60, with a volume of 2.04M.
It is up +1.31% in the last 24 hours and down -6.89% over the past month.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
See More
Previous Close:
$42.05
Open:
$41.66
24h Volume:
2.04M
Relative Volume:
2.72
Market Cap:
$2.70B
Revenue:
-
Net Income/Loss:
$-107.85M
P/E Ratio:
-12.68
EPS:
-3.36
Net Cash Flow:
$-106.82M
1W Performance:
-3.29%
1M Performance:
-6.89%
6M Performance:
+19.46%
1Y Performance:
+180.45%
1-Day Range:
$40.96
$45.06
1-Week Range:
$40.73
$45.27
52-Week Range:
$14.20
$51.61
Vera Therapeutics Inc Stock (VERA) Company Profile
Name
Vera Therapeutics Inc
Sector
Industry
Phone
650-770-0077
Address
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Compare VERA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
42.60 | 2.70B | 0 | -107.85M | -106.82M | -2.21 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-21-24 | Initiated | Wells Fargo | Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jan-25-24 | Initiated | Oppenheimer | Outperform |
| Jan-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-18-23 | Initiated | Raymond James | Outperform |
| Nov-10-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-16-23 | Initiated | Guggenheim | Buy |
| Jan-04-23 | Downgrade | Jefferies | Buy → Hold |
| Jan-04-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-12-22 | Initiated | JP Morgan | Overweight |
| May-02-22 | Initiated | H.C. Wainwright | Buy |
| Apr-19-22 | Initiated | Wedbush | Outperform |
View All
Vera Therapeutics Inc Stock (VERA) Latest News
Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Sells $753,725.00 in Stock - MarketBeat
Vera Therapeutics Insider Sold Shares Worth $753,680, According to a Recent SEC Filing - Marketscreener.com
Wellington Management Group LLP Sells 92,568 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - MarketBeat
Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Sold by State Street Corp - MarketBeat
Lord Abbett & CO. LLC Increases Position in Vera Therapeutics, Inc. (NASDAQ:VERA) - MarketBeat
Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Certain Class A common stock of Vera Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 15-DEC-2024. - Marketscreener.com
Marshall Fordyce Sells 17,500 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) Stock - MarketBeat
Vera Therapeutics CEO sells shares worth over $821k By Investing.com - Investing.com Canada
Vera Therapeutics CEO sells shares worth over $821k - Investing.com
Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Purchased by Y Intercept Hong Kong Ltd - MarketBeat
VERAVera Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Vera Therapeutics Grants $8.5M in Stock Options, RSUs to Attract Key Talent - StockTitan
Pier Capital LLC Invests $4.57 Million in Vera Therapeutics, Inc. (NASDAQ:VERA) - MarketBeat
Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Purchased by Point72 Asset Management L.P. - MarketBeat
Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Bought by Charles Schwab Investment Management Inc. - MarketBeat
Verition Fund Management LLC Invests $1.91 Million in Vera Therapeutics, Inc. (NASDAQ:VERA) - MarketBeat
Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Sold by Readystate Asset Management LP - MarketBeat
Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Sold by Fmr LLC - MarketBeat
Vera Therapeutics, Inc. (NASDAQ:VERA) Stock Holdings Lifted by HighVista Strategies LLC - MarketBeat
Cinctive Capital Management LP Has $2.14 Million Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) - MarketBeat
Intech Investment Management LLC Buys New Shares in Vera Therapeutics, Inc. (NASDAQ:VERA) - MarketBeat
Intech Investment Management LLC Purchases New Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Analysts Set Vera Therapeutics, Inc. (NASDAQ:VERA) Target Price at $59.22 - MarketBeat
Objective long/short (VERA) Report - Stock Traders Daily
Vera Therapeutics Grants 161,000 Share Awards to New Chief Legal Officer | VERA Stock News - StockTitan
Wells Fargo Initiates Coverage of Vera Therapeutics (VERA) with Overweight Recommendation - MSN
Vera Therapeutics initiated with an Overweight at Wells Fargo - MSN
Vera Therapeutics (NASDAQ:VERA) Coverage Initiated at Wells Fargo & Company - MarketBeat
GSA Capital Partners LLP Has $535,000 Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) - MarketBeat
Wall Street Analysts Think Vera Therapeutics (VERA) Could Surge 27.26%: Read This Before Placing a Bet - MSN
Calif. Biotech Firm Vera Taps Veteran Chief Legal Officer - Law360
First Turn Management LLC Increases Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) - MarketBeat
Vera hires Jason Carter as chief legal officer - BioCentury
Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer - GlobeNewswire
Vera Therapeutics Appoints Former Kite Pharma Legal Head as Chief Legal Officer | VERA Stock News - StockTitan
Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer By Investing.com - Investing.com Canada
Vera Therapeutics Inc (VERA) Stock Price & Chart | Trade Now - Capital.com
(VERA) Proactive Strategies - Stock Traders Daily
COMMODORE CAPITAL LP Adjusts Stake in Vera Therapeutics Inc - GuruFocus.com
Kynam Capital Management, LP Increases Stake in Vera Therapeutics Inc - GuruFocus.com
500: Something went wrong - Investing.com India
Vera Therapeutics stock soars to all-time high of $50.98 - Investing.com
Vera Therapeutics stock soars to all-time high of $50.98 By Investing.com - Investing.com Australia
Vera Therapeutics (NASDAQ:VERA) Reaches New 1-Year HighHere's What Happened - MarketBeat
FMR LLC Reduces Stake in Vera Therapeutics Inc - GuruFocus.com
Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study - The Manila Times
Vera Therapeutics (NASDAQ:VERA) Posts Quarterly Earnings Results, Misses Expectations By $0.21 EPS - MarketBeat
Vera Therapeutics to Participate at Upcoming Investor Conferences - The Manila Times
Vera Therapeutics Inc Stock (VERA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vera Therapeutics Inc Stock (VERA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Fordyce Marshall | PRESIDENT AND CEO |
Dec 18 '24 |
Option Exercise |
2.90 |
17,500 |
50,694 |
90,965 |
| Fordyce Marshall | PRESIDENT AND CEO |
Dec 18 '24 |
Sale |
43.07 |
17,500 |
753,680 |
85,942 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):